---
run_id: halo-evidence-vs-diagnosis-validation-v7-vanilla-08
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: vanilla
run_number: 8
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 801
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
condition_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
output_file: model-outputs/vanilla-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `vanilla`, run 8 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 801, on the frozen condition packet.

## Output

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current "upbeat" narrative is a lagging indicator built on financial engineering, not product-market fit. The expansion revenue is artificial—driven by six-month discounts that essentially "borrow" future revenue to mask current instability. More critically, you have a "Champion Gap": the feature is being used by the people who *manage* the software (compliance ops), but is being rejected by the people who *do* the work (front-line reviewers).

In compliance software, the user is not the buyer, but the user is the one who determines the renewal. A 31% first-week retention rate among reviewers is a catastrophic signal. If you scale now (Option A), you are scaling a product that front-line users find useless or inexplicable, which will lead to a massive churn event once the early-renewal discounts expire and the "nonrenewal letters" currently hiding in procurement become official. You are currently repeating the exact "bespoke and reactive" behaviors that leadership previously criticized, just with a different set of metrics.

**The strongest reason against this:**
It kills the current internal momentum and risks the CEO’s political capital with the board. The board is currently happy; they see rising NRR and a "disciplined" team. Recommending a "pause" on discounts and a "test" of the strategy effectively tells the board that the current victory is an illusion. In a high-growth environment, "slowing down to get the data right" is often interpreted as a lack of confidence or an inability to execute, which could jeopardize the budget or the CEO's standing.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" (Option A) if you could demonstrate that the 31% reviewer retention rate is a "training" issue rather than a "value" issue. Specifically: if a cohort of reviewers who received a specific, lightweight onboarding intervention (not a full training course) saw their retention jump to >60% without any changes to the product. This would prove the "wedge" is real and the friction is merely educational, making the risk of scaling acceptable.
